|
Daehan New Pharm achieved operating profit of 12.2 billion won in the second quarter, which is a 12.8% increase compared to the same period last year
2020.08.13
|
|---|
|
In the second quarter of 2020, Daehan New Pharm recorded cumulative sales of approximately 74.2 billion won, marking an 11.2% increase compared to the same period last year. Thanks to strengthened distribution management, portfolio enhancement, and consistent sales of existing key products, the company achieved an operating profit of 12.2 billion won, up 12.8% year-on-year, with an operating margin of 16.5%. Net profit also maintained a positive trend at 7.5 billion won, representing a net profit margin of 10.1%, compared to the same period last year.
Steady profits were generated in the core areas of obesity and well-being pharmaceuticals, with the animal medicine business particularly driving sales growth. To sustain this momentum in the second half, the company has established detailed execution strategies by business division and is committed to strengthening its pipeline based on a new long-term vision to become a better company tomorrow. |


Home